Brainstorm Cell Therapeutics, Inc.

+0.66 (+6.94%)
4:03:59 PM EDT: $10.28 +0.11 (+1.08%)
Earnings Announcements

Brainstorm Cell Therapeutics Reports Q3 Loss Per Share Of $0.14

Published: 10/15/2020 11:14 GMT
Brainstorm Cell Therapuetics Inc (BCLI) - Brainstorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update.
Q3 Loss per Share $0.14.
Q3 Earnings per Share Estimate $-0.26 -- Refinitiv Ibes Data (analyst estimates).
Pivotal Phase 3 Als Trial Remains on Track for Top-line Data Readout by End of November 2020.
Cash and Cash Equivalents, and Short-term Bank Deposits Amounted to Approximately $28.8 Million at September 30, 2020.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.42

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.